AKTX Akari Therapeutics PLC ADRs

Akari Therapeutics PLC is a biopharmaceutical company in clinical stage. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$1.70
As of 10/18/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  United Kingdom
Country of incorporation:  United Kingdom
IPO date:  05/07/2013
Outstanding shares:  47,597,330
Average volume:  111,850
Market cap:   $78,059,621
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    00972G108
ISIN:        US00972G1085
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   10.65
PS ratio:   0.00
Return on equity:   -1,042.08%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy